Welcome to our dedicated page for Terumo news (Ticker: TRUMY), a resource for investors and traders seeking the latest updates and insights on Terumo stock.
The news page for TERUMO CORP UNSP/ADR (TRUMY) aggregates company-related announcements tied to Terumo Corporation, a medical technology company active in vascular intervention, neurovascular devices, blood and cell technologies, and digital health tools. Recent releases highlight developments from divisions and subsidiaries such as Terumo Neuro, Terumo Interventional Systems, Terumo Health Outcomes, and Terumo Blood and Cell Technologies.
Readers can find updates on neurovascular and stroke treatment devices, including Terumo Neuro’s SOFIA 88 Neurovascular Support Catheter and its broader stroke portfolio of aspiration catheters, retrieval devices, balloon guide catheters, microcatheters, and guidewires. News also covers regulatory milestones such as FDA approval for a dual-layer micromesh carotid stent system and data presentations at professional conferences.
Coverage extends to interventional cardiology and peripheral interventions through Terumo Interventional Systems, with announcements on products like the ROADSAVER Carotid Stent System and R2P NaviCross peripheral support catheter. These items illustrate Terumo’s focus on minimally invasive entry site management, lesion access, and endovascular treatment technologies.
Additional articles describe digital health and decision support initiatives from Terumo Health Outcomes, including the ePRISM precision medicine platform and collaborations around Medis QFR software for coronary physiology assessment. Terumo Blood and Cell Technologies contributes news on blood and cell therapy technologies, such as the Spectra Optia Apheresis System and research on automated red blood cell exchange for sickle cell disease.
Investors and healthcare professionals can use this news feed to follow product launches, clinical data, partnerships, and technology updates associated with the TRUMY ADR’s underlying company. Bookmark this page to access an organized view of Terumo-related press releases and developments as they are reported.
Terumo Interventional Systems has launched its R2P NaviCross peripheral support catheter in the U.S., expanding its radial-to-peripheral portfolio. The new 200 cm length catheter features double-braided, stainless-steel construction for enhanced trackability and torque control in complex procedures. This addition complements Terumo's existing R2P portfolio, which includes the Destination Slender guiding sheath, SlenGuide guiding catheter, Misago self-expanding peripheral stent, and other specialized catheters. The device is specifically designed for treating peripheral artery disease (PAD) and critical limb ischemia through radial access procedures.
Terumo Blood and Cell Technologies has completed a meta-analysis demonstrating the effectiveness of automated red blood cell exchange (aRBCX) in improving quality of life for sickle cell disease (SCD) patients. The study, published in Vox Sanguinis, analyzed over two decades of research and showed that aRBCX leads to shorter hospital stays, reduced procedure times, and fewer pain-related hospitalizations.
The research supports patient testimonials about aRBCX's benefits in managing SCD complications. The company's Spectra Optia™ Apheresis System is used to remove sickled cells from patients' blood. The study also highlighted the need for further research on psychosocial aspects of treatment.
Terumo has established Terumo Ventures, a Corporate Venture Capital (CVC) organization within Terumo Americas Holding, aimed at leading the Group's venture investments. Terumo Ventures will invest US$ 75 million over the next five years in early-stage companies in fields like cardiovascular disease, chronic disease treatment, and digital technologies. The CVC operates in global innovation hubs, such as Massachusetts and California.
Since 2013, Terumo has been building relationships with medtech start-ups through investments in venture capital funds in the US and China. The new CVC aims to increase agility in identifying and executing venture investments, accelerating the acquisition of cutting-edge technologies, and developing a robust M&A pipeline.
Aligned with its 5-Year Growth Strategy 'GS26' and long-term vision 'From Devices to Solutions,' Terumo aims to enhance innovation capabilities. This includes a new director position managing innovation-related functions and fostering cross-functional collaboration.
Terumo Cardiovascular announced that the U.S. FDA has granted 510(k) clearance for its CDI OneView Monitoring System. This next-generation platform can measure and display up to 22 key patient parameters during cardiopulmonary bypass surgery, enhancing perfusion safety and patient outcomes. Key new parameters include measured flow (Q), cardiac index (CI), and regional cerebral oxygen saturation (rSO2). The system's modular design allows for flexible configuration to meet clinical needs. Terumo emphasized the system's development was influenced by extensive feedback from global cardiovascular experts and is aimed at reducing complications such as acute kidney injury.
Terumo Blood and Cell Technologies (Terumo BCT) received FDA clearance for the Rika Plasma Donation System with the iNomi Nomogram, a new innovation that allows plasma donors to donate the right amount of plasma based on their individual characteristics. This system aims to increase collection volume without extending collection time, with an average 10% increase in plasma volume collected per donation in less than 35 minutes. Rika is designed for donor comfort and safety, ensuring a seamless and efficient experience for plasma donors and collection center employees. This innovation is expected to enhance patient access to care and support the needs of patients relying on plasma-derived therapies.
Summary not available.
Summary not available.
Terumo Medical Corporation announced the final results of its R.A.V.I. study, highlighting the safety and efficacy of radial artery access in embolization procedures for conditions such as uterine fibroids and hypervascular tumors. The study, involving 99 patients across six hospitals, demonstrated a 100% procedural success rate with significant patient benefits, including same-day discharge for 74.7% of participants. Presenting the findings at the SIR 2023 Annual Scientific Meeting, Dr. Guimaraes emphasized the potential of radial access to become the preferred method in various embolization procedures. Terumo continues to innovate in interventional techniques.
Terumo Blood and Cell Technologies has received FDA clearance for its IMUGARD® WB Platelet Pooling Set, which extends the shelf life of whole blood-derived platelets from five days to seven days. This innovation aims to address the increasing demand for platelets amid a declining supply due to the shortage of blood donors. In the U.S., over 2.5 million units of platelets were transfused in 2021. The IMUGARD system provides an alternative source for blood centers to manage platelet supply effectively and reduce waste, benefitting patients in need of transfusions.
On November 1, 2022, a study published in JAMA showcased that Terumo Health Outcomes' ePRISM software effectively reduced the risk of acute kidney injury (AKI) in high-risk patients undergoing percutaneous coronary interventions. The three-year randomized study involved 31 cardiologists and 7,106 patients, revealing that AKI rates dropped significantly from 51.7% to 38.1% when using ePRISM. The platform’s personalized contrast volume guidelines not only enhance patient care but could also lead to improved hospital performance metrics and reduced healthcare costs.